BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 22805618)

  • 1. An overview of immunosuppressive therapy in idiopathic membranous nephropathy.
    Maas R; Hofstra JM; Wetzels JF
    Minerva Med; 2012 Aug; 103(4):253-66. PubMed ID: 22805618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.
    Chen Y; Schieppati A; Chen X; Cai G; Zamora J; Giuliano GA; Braun N; Perna A
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD004293. PubMed ID: 25318831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group.
    Branten AJ; Wetzels JF
    Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial.
    Hofstra JM; Branten AJ; Wirtz JJ; Noordzij TC; du Buf-Vereijken PW; Wetzels JF
    Nephrol Dial Transplant; 2010 Jan; 25(1):129-36. PubMed ID: 19666912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The late results of treating membranous glomerulonephritis].
    Belovezhdov N; Robeva R; Dimitrova V
    Vutr Boles; 1990; 29(3):53-60. PubMed ID: 2284800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive treatment of idiopathic membranous nephropathy: the dilemma continues.
    Filippone EJ
    Clin Nephrol; 2013 Feb; 79(2):143-53. PubMed ID: 23211341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity.
    du Buf-Vereijken PW; Wetzels JF
    Nephrol Dial Transplant; 2004 Aug; 19(8):2036-43. PubMed ID: 15187191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy.
    du Buf-Vereijken PW; Branten AJ; Wetzels JF
    Am J Kidney Dis; 2005 Dec; 46(6):1012-29. PubMed ID: 16310567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study.
    Cravedi P; Sghirlanzoni MC; Marasà M; Salerno A; Remuzzi G; Ruggenenti P
    Am J Nephrol; 2011; 33(5):461-8. PubMed ID: 21508634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate.
    du Buf-Vereijken PW; Branten AJ; Wetzels JF;
    Nephrol Dial Transplant; 2004 May; 19(5):1142-8. PubMed ID: 14993502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of idiopathic membranous nephropathy.
    Hofstra JM; Fervenza FC; Wetzels JF
    Nat Rev Nephrol; 2013 Aug; 9(8):443-58. PubMed ID: 23820815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy.
    Hofstra JM; Deegens JK; Willems HL; Wetzels JF
    Nephrol Dial Transplant; 2008 Aug; 23(8):2546-51. PubMed ID: 18308774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Application of guidelines in clinical practice: a multicenter analysis of the treatment of membranous glomerulonephritis in Piedmont, Italy].
    Rollino C; Coppo R; Giacchino F; Savoldi S; Manganaro M; Amore A; Colla L; Ferro M; Demicheli G; Berutti S; Burdese M; Paternoster G; Cravero R; Benozzi L; Vagelli G; Messuerotti A; Licata C; Bainotti S; Patti RR; Quaglia M; Costantini L; Stratta P; Segoloni G;
    G Ital Nefrol; 2010; 27(6):639-48. PubMed ID: 21132646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of current and alternative therapies for idiopathic membranous nephropathy.
    Tran TH; J Hughes G; Greenfeld C; Pham JT
    Pharmacotherapy; 2015 Apr; 35(4):396-411. PubMed ID: 25884528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACTH and azathioprine: antiproteinuric and lipid-lowering effect in the course of idiopathic membranous glomerulonephritis.
    Gigante A; Rosato E; Liberatori M; Gasperini ML; Giannakakis K; Barbano B; Cianci R; Salsano F; Amoroso A
    J Biol Regul Homeost Agents; 2012; 26(1):135-8. PubMed ID: 22475105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis.
    Dumoulin A; Hill GS; Montseny JJ; Meyrier A
    Am J Kidney Dis; 2003 Jan; 41(1):38-48. PubMed ID: 12500220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiopathic membranous nephropathy: diagnosis and treatment.
    Fervenza FC; Sethi S; Specks U
    Clin J Am Soc Nephrol; 2008 May; 3(3):905-19. PubMed ID: 18235148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spontaneous remission of nephrotic syndrome in membranous nephropathy with chronic renal impairment.
    Polanco N; Gutiérrez E; Rivera F; Castellanos I; Baltar J; Lorenzo D; Praga M;
    Nephrol Dial Transplant; 2012 Jan; 27(1):231-4. PubMed ID: 21624942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of idiopathic membranous nephropathy].
    Passerini P
    G Ital Nefrol; 2004; 21(6):531-9. PubMed ID: 15593020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study.
    Goumenos DS; Ahuja M; Davlouros P; El Nahas AM; Brown CB
    Clin Nephrol; 2006 May; 65(5):317-23. PubMed ID: 16724651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.